Funded Biotechnology Startups in Woburn
Among the 13 Woburn-area biotechnology companies shown, the largest disclosed round is Sanegene Bio’s $110M (Series B) on 2025-12-08.
Among the 13 Woburn-area biotechnology companies shown, the largest disclosed round is Sanegene Bio’s $110M (Series B) on 2025-12-08. That figure stands out against the rest of the disclosed amounts: several are clustered at $3M (Hopewell Therapeutics on 2025-09-21; Rational Vaccines on 2023-10-13), with one additional high point at Replimune Group’s $140M on 2024-11-25, while other disclosed rounds include $60M (Neurogastrx, 2021-08-26), $40M (MarvelBiome, 2025-10-22), and smaller checks like $10M (AlpalifeBio, 2025-09-09) and $5M (Fieldstone Bio, 2025-05-15).
The list is temporally back-loaded into late 2024 through late 2025: 9 of 13 entries have round dates from 2024-06-07 to 2025-12-27, with the most recent entry being 100XBIO (pre-seed) on 2025-12-27 (undisclosed). Stage reporting is skewed toward ambiguity or non-disclosed terms: 5 of 13 rows are “Series Unknown” and 3 of 13 are “undisclosed,” making disclosed comparisons most reliable for the remaining subset (e.g., Series B appears for Sanegene Bio, Replimune Group, and Neurogastrx). Geographically, all rows list Woburn, Massachusetts (one row repeats “Woburn, United States” for AlpalifeBio).
Most recent rounds
13 shownRelated listings
Frequently asked
What’s the largest disclosed round in this Woburn biotechnology set, and how far above the rest is it?
Replimune Group’s $140M (Series Unknown) on 2024-11-25 is the largest disclosed amount in the table. It is materially above the next-largest disclosed rounds visible here, including Sanegene Bio’s $110M on 2025-12-08 and Neurogastrx’s $60M on 2021-08-26.
Are round dates clustered, or are they spread out evenly across years?
Dates concentrate heavily in the latest window: 9 of 13 entries fall between 2024-06-07 (Purinomia Biotech) and 2025-12-08 (Sanegene Bio). The oldest dated row shown is Neurogastrx on 2021-08-26, creating a clear temporal edge between 2021 and the 2024–2025 cluster.
Which parts of the table are most usable for size comparisons given missing or ambiguous amounts and stages?
Undisclosed amounts appear in 3 of 13 rows (100XBIO on 2025-12-27; Leveragen on 2025-07-25; Abpro on 2024-11-13), while 5 of 13 rows use “Series Unknown” (e.g., MarvelBiome on 2025-10-22 for $40M and Replimune Group on 2024-11-25 for $140M). This means disclosed-and-labeled comparisons are limited to the remaining rows with explicit dollar figures (such as Sanegene Bio’s $110M and Fieldstone Bio’s $5M).
Does Woburn show a stage mix skew within the disclosed entries?
Explicit “Series B” is repeated 3 times in this set: Sanegene Bio ($110M on 2025-12-08), Replimune Group ($140M on 2024-11-25), and Neurogastrx ($60M on 2021-08-26). By contrast, other explicit stages shown include Seed (Fieldstone Bio, $5M on 2025-05-15) and Series A (AlpalifeBio, $10M on 2025-09-09), with multiple entries staying at “Series Unknown.”
Any outliers worth flagging beyond the largest dollar figure?
Yes. The combination of Replimune Group’s $140M on 2024-11-25 and Neurogastrx’s $60M on 2021-08-26 creates an upper band that sits well above smaller disclosed rounds like Purinomia Biotech’s $1M (2024-06-07) and multiple $3M entries (Hopewell Therapeutics on 2025-09-21; Rational Vaccines on 2023-10-13). At the low end, Purinomia Biotech’s $1M (smallest disclosed amount) is the only $1M-level round in the visible disclosed set.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.